Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Innovative approaches in the design of T cell-engaging (TCE) molecules are ushering in a new wave of promising immunotherapies for the treatment of cancer. Their mechanism of action, which generates an in trans interaction to create a synthetic immune synapse, leads to complex and interconnected rel...
Saved in:
Main Authors: | Kathryn Ball, Simon J Dovedi, Pavan Vajjah, Alex Phipps |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2181016 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships
by: Nicolas Simon, et al.
Published: (2025-07-01) -
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
by: Joshuaine Grant, et al.
Published: (2023-12-01) -
Current advances in bispecific T cell–engaging therapies
by: Emmanuel Owusu Ansah, et al.
Published: (2025-04-01) -
Minimising Toxicity and Maximising Response: T-Cell Engagers for Elderly Patients with Multiple Myeloma
by: Anthony McLoughlin, et al.
Published: (2025-06-01) -
Producing and prospects for the use of bispecific antibodies for the treatment of cancer
by: S. E. Sedykh, et al.
Published: (2019-01-01)